Ventral striatal D3 receptors and Parkinson's Disease

Parkinsonism and Related Disorders

Volumn 7, Issue 3, 2001, Pages 225-230

  Joyce, J N ^a   Ryoo, H ^a   Gurevich, E V ^a   Adler, C ^b   Beach, T ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Alzheimer's Disease; Basal ganglia; Dopamine; Limbic system; Ventral tegmental area

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; LEVODOPA;

BRAIN REGION; CONFERENCE PAPER; DEMENTIA; DRUG SENSITIVITY; HUMAN; MESOLIMBIC DOPAMINERGIC SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY;

EID: 0035029099     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(00)00060-2     Document Type: Conference Paper

References (61)

1. Biochemical aspects of Parkinson's disease
2. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I
3. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II
4. Frequency of dementia in Parkinson disease
5. The occurrence of depression in Parkinson's disease. A community-based study
6. Risk factors for depression in Parkinson disease
7. Clinico-pathological correlations in Parkinson's disease
8. An estimate of the prevalence of dementia in idiopathic Parkinson's disease
9. Clinical features predicting dementia in idiopathic Parkinson's disease: a follow-up study
10. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test
11. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, 'prefrontal' and 'limbic' functions
12. Functional anatomy of the basal ganglia I. The cortico-basal ganglia-thalamo-cortical loop
13. The concept of the ventral striatum in nonhuman primates
14. Influence of dopamine on limbic inputs to the nucleus accumbens
15. Post mortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms?
16. Nigral degeneration in Parkinson's disease in relation to clinical features
17. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?
18. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender
19. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway
20. The neural mechanisms and progressive nature of symptoms of Parkinson's disease - based on clinical, neurophysiological and morphological studies
21. Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia
22. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets
23. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in the common marmoset
24. Dopamine D1 receptor agonists. The way forward for the treatment of Parkinson's Disease?
25. Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates
26. Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study
27. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis
28. The effect of chronic L-dopa administration on supersensitive pre- and postsynaptic dopaminergic receptors in rat brain
29. Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum
30. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA
31. Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with the D1 and D2 dopamine receptors
32. D1/D3 receptor relationships in brain coexpression, coactivation, and coregulation
33. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies [In Process Citation]
34. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons
35. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain
36. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease
37. 11C]raclopride
38. 11C-N-methyl- spiperone
39. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography
40. 123I]-IBZM SPET study
41. Dopamine D2 receptor density remains constant in treated Parkinson's disease
42. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases
43. 3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy
44. Striatal dopaminergic markers in dementia with lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution
45. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases
46. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons
47. Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment
48. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease
49. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease
50. Differential effects of limbic versus striatal dopamine loss on motoric function
51. Functional recovery after destruction of dopamine systems in the nucleus accumbens of rats. I. Behavioral and biochemical studies
52. Depletion of dopamine in the nucleus accumbens prevents the generation of locomotion by metabotropic glutamate receptor activation
53. Behavioral functions of nucleus accumbens dopamine: empirical and conceptual problems with the anhedonia hypothesis
54. Complex motor and sensorimotor functions of striatal and accumbens dopamine: involvement in instrumental behavior processes
55. A neurochemical and behavioral investigation of the involvement of nucleus accumbens dopamine in instrumental avoidance
56. Spatial localization in the Morris water maze in rats: acquisition is affected by intra-accumbens injections of the dopaminergic antagonist haloperidol
57. Pramipexole in patients with early Parkinson's disease
58. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease
59. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group [published erratum appears in Neurology 1998 50:838]
60. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine monkeys
61. Behavioral effects of selective dopamine D3 receptor agonist/antagonist in primate model of Parkinson's disease